基于CIBERSORT方法评价肿瘤浸润免疫细胞与肝细胞癌预后的关系:一项TCGA数据集二次分析  

Evaluation of the relationship between tumor-infiltrating immune cells and the prognosis of hepatocellular carcinoma based on CIBERSORT method:a secondary analysis of TCGA dataset

作　　者：张文思[1] 陈晓蓉[1] 杨宗国[1] ZHANG Wen-si;CHEN Xiao-rong;YANG Zong-guo(Department of Traditional Chinese medicine department,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China)

机构地区：[1]上海市公共卫生临床中心中医科,上海201508

出　　处：《中西医结合肝病杂志》2023年第6期500-503,508,共5页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：上海市科委医学引导类项目(No.19401931600)。

摘　　要：目的:本研究拟评价肿瘤浸润免疫细胞与肝细胞癌(HCC)患者预后的关系。方法:采用CIBERSORT方法分析并识别癌症基因组图谱(TCGA)数据库肝细胞癌数据集(LIHC)中特定类型的肿瘤浸润免疫细胞。通过Log rank方法评估肿瘤浸润免疫细胞与HCC患者预后的关系。结果:在TCGA-LIHC数据集中,以CIBERSORT P<0.05为标准纳入30例肿瘤样本和2例非肿瘤样本。与非肿瘤组织相比,巨噬细胞M0在肿瘤组织中显著浸润(P<0.05)。HCC患者非肿瘤组织中的巨噬细胞M1显著高于肿瘤组织中的巨噬细胞(P<0.05)。肿瘤中高巨噬细胞M0与HCC患者较差的总生存期(OS)和无病生存期(DFS)显著相关(分别为HR=2.06,95%CI=1.45~2.93,Log rank P<0.001和HR=1.58,95%CI=1.17~2.14,P=0.004)。而HCC患者巨噬细胞M1与OS和DFS无显著性差异(P>0.05)。在甲胎蛋白升高、AJCC分期晚期、TNM分级晚期和血管浸润的HCC患者中,巨噬细胞M0的CIBERSORT分数显著增加(均P<0.05)。结论:肿瘤浸润巨噬细胞M0可加速HCC进展并导致不良预后,应考虑作为HCC治疗的治疗靶点。Objective:The aim of this study was to evaluate the relationship between tumor-infiltrating immune cells and the prognosis of patients with hepatocellular carcinoma(HCC).Methods:CIBERSORT method was used to analyze and identify specific types of tumor-infiltrating immune cells in the Cancer Genome Atlas(TCGA)hepatocellular carcinoma dataset(LIHC).The relationship between tumor-infiltrating immune cells and the prognosis of HCC patients was evaluated by Log rank method.Results:In TCGA-LIHC dataset,30 tumor samples and 2 nontumor samples were selected while CIBERSORT p-value<0.05 was acquired.Macrophages M0 was significantly infiltrated in tumor tissues compared with that in nontumor tissues(P<0.05).M1 macrophages in non-tumor tissues of HCC patients were significantly higher than those in tumor tissues(P<0.05).High macrophages M0 in tumors was significantly correlated with poorer overall survival(OS)and disease-free survival(DFS)in HCC patients(HR=2.06,95%CI=1.45~2.93,Log rank P<0.001 and HR=1.58,95%CI=1.17~2.14,Log rank P=0.004,respectively).While no significances were found between macrophages M1 and OS and DFS in HCC patients(both P>0.05).CIBERSORT fraction of macrophages M0 was significantly increased in HCC patients with alpha-fetoprotein elevation,advanced American Joint Committee on Cancer(AJCC)stage,advanced neoplasm histologic grade and vascular invasion(all P<0.05).Conclusion:Tumor-infiltrating macrophages M0 could accelerate HCC progression and contribute to poor outcomes,which should be considered as therapeutic target for HCC treatment.

关 键 词：巨噬细胞 肝细胞癌 肝癌 免疫细胞 生存期 

分 类 号：R392.7[医药卫生—免疫学]